Royal Bank Of Canada Cuts Oxford Biomedica (LON:OXB) Price Target to GBX 900

Oxford Biomedica (LON:OXB) had its price objective reduced by Royal Bank Of Canada from GBX 1,140 to GBX 900 in a research report sent to investors on Monday, Marketbeat Ratings reports. Royal Bank Of Canada currently has an outperform rating on the biopharmaceutical company’s stock.

Separately, Jefferies Financial Group reissued a “buy” rating and issued a GBX 8.27 price objective on shares of Oxford Biomedica in a research report on Tuesday, June 2nd. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of GBX 621.85.

Oxford Biomedica Trading Up 1.1%

LON:OXB opened at GBX 492.50 on Monday. Oxford Biomedica has a twelve month low of GBX 423.50 and a twelve month high of GBX 952. The company has a quick ratio of 1.67, a current ratio of 2.20 and a debt-to-equity ratio of 162.16. The business has a 50 day moving average price of GBX 595.77 and a two-hundred day moving average price of GBX 639.66. The company has a market cap of £596.11 million, a P/E ratio of -18.29 and a beta of 1.10.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.